Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
Nat Rev Rheumatol. 2022 Jan 5:1–13. Epub ahead of print doi: 10.1038/s41584-021-00726-8
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Nat Rev Rheumatol. 2022 Jan 5:1–13. Epub ahead of print doi: 10.1038/s41584-021-00726-8
Clin Rheumatol. 2022 Jan 1. Epub ahead of print doi: 10.1007/s10067-021-05908-z
Clin Rheumatol. 2022. Epub ahead of print doi: 10.1007/s10067-021-06003-z
Ann Rheum Dis. 2022 Jan 13. Epub ahead of print doi: 10.1136/annrheumdis-2021-221915
Rheumatol Ther. 2021. Epub ahead of print. doi: 10.1007/s40744-021-00390-0
ACR Open Rheumatol. 2021. Epub ahead of print. doi: 10.1002/acr2.11380
Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab861
J Clin Rheumatol. 2021;27(8):e482–e490
J Crohns Colitis. 2022 Jan 28;16(1):27-38 doi: 10.1093/ecco-jcc/jjab133
The authors highlighted a significantly greater clinical remission rate at Week 52 for vedolizumab SC versus placebo in patients with moderately to severely active CD. This study aimed to report results from VISIBLE 2 which evaluated a new SC vedolizumab formulation as maintenance treatment in adults with moderately to severely active CD.